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C. albicans ATCC 10231Resistance to currently available antifungal drugs necessitates development of newdrugs using rapid, robust and
automatedmethods to test a large number of newly synthesized drugs in less time.Wehave compared the effect
of ketoconazole,ﬂuconazole and its synthesized analogues onCandidaalbicansATCC10231.Ametabolicproﬁle of
C. albicans ATCC 10231 in presence of drugs has been compared using 1H NMR. Signals from metabolites have
been monitored with time. MIC determined using conventional methods has been compared with
Metabolic End Point (MEP) obtained from NMR spectroscopy. Results indicate that the activity of the
ﬂuconazole derivatives is in the order ﬂuconazole p-methoxybenzoateNﬂuconazole=ﬂuconazole
benzoateNﬂuconazole toluateNﬂuconazole p-nitrobenzoate.on; MEP, Metabolic End Point;
enzoate; FZ_pnb, Fluconazole
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Azoles are the most extensively used group of synthetic fungistatic
agents with a broad spectrum of activity. They act by inhibiting fungal
cytochrome P450 3A (CYP3A) enzyme, lanosterol 14α-demethylase,
which is responsible for converting lanosterol to ergosterol, the main
sterol in the fungal cell membrane [1]. The resulting depletion of
ergosterol alters the ﬂuidity of the membrane and interferes with the
action of membrane associated enzymes. Ketoconazole (KZ) (Fig. 1) is
an orally and topically administered imidazole with a broad spectrum
of activity, used to treat mucosal and cutaneous infections caused by
Candida species [2]. Fluconazole (FZ) (Fig. 1) is a triazole derivative, an
oral anti-fungal drug with low toxicity and inhibits speciﬁc steps in
fungal sterol biosynthesis [3]. It has been shown to be effective against
some systemic mycoses, in particular those caused by opportunistic
yeasts of the genus Candida [4]. However, in clinical practice,
problems arise due to extensive use of FZ, particularly in the presence
of Candida species that are intrinsically resistant or species that
rapidly acquire resistance [3]. The emergence of such resistance has
created a need for new and effective antifungal agents with high
susceptibility towards fungal cell. In order to increase antifungalpotency and susceptibility, it is necessary to increase the overall
lipophilicity of these agents. The results on the quantitative structure
activity relationship (QSAR) study show good predictive ability for
antifungal activity of ﬂuconazole derivatives [5].
In view of this we have synthesized different carboxylic acid ester
derivatives of Fluconazole: ﬂuconazole benzoate (FZ_bz), ﬂuconazole
p-nitrobenzoate (FZ_pnb), ﬂuconazole p-methoxybenzoate
(FZ_pmb), ﬂuconazole toluate (FZ_tol) to increase the lipophilicity
(Fig. 1). The enhanced lipophilicity of the ester analogues helps in
fungal cell penetration as well as enables to undergo cellular
biotransformation through hydrolysis or enzymatic cleavage to FZ
and carboxylic acid counterpart. The dual component obtained after
the hydrolysis of the conjugate may enhance the fungal cell
susceptibility by targeting different fungal receptors thus reducing
the chance of fungal resistance [6].
Nuclear magnetic resonance (NMR) spectroscopy can be used to
identify the metabolic components of the micro-organisms. The
conventional methods mainly based on the virtual comparison of the
fungal growth require long turnaround time. NMR based observations
found to be reproducible, precedes detectable inhibition of microbial
growth by conventional means and prepares a platform for rapid
determination for the susceptibility to the drugs [7].
In the present study we have compared the effect of ketoconazole,
ﬂuconazole and ﬂuconazole analogues on metabolism of Candida
albicans ATCC 10231 by monitoring production of fungal metabolites
such as ethanol, lactate, acetate, etc. and determined metabolic end
point (MEP) using 1HNMR spectra. MEP is the lowest concentration of
drug at which fungal metabolite production was inhibited by at least
50% [7]. Results have been supported by conventional tube dilution
Fig. 1. Molecular structure of ketoconazole, ﬂuconazole and ﬂuconazole analogues.
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Institute (CLSI) method [10]. MIC obtained from the conventional
methods, is the lowest concentration of drug that inhibits the visible
growth of a micro-organism after incubation for 48 h [11].
2. Materials and methods
2.1. Materials
Fluconazole and Ketoconazole were gift samples from Aurochem
Pharmaceuticals Pvt. Ltd. India and Kemwell Pvt. Ltd., respectively.
Sabouraud dextrose agar, Sabouraud dextrose broth and RPMI-1640
were purchased from HiMedia laboratories Pvt. Ltd. India, Dimethyl
sulfoxide was purchased from Sigma chemical company USA. 3-
morpholinopropane sulphonicacid (MOPS) was purchased from SRL
Pvt. Ltd. All chemicals were used without further puriﬁcation.
2.2. Chemistry
The ﬂuconazole (FZ) analogues FZ_bz and FZ_pnb were synthe-
sized by reacting FZ with corresponding acid chlorides. Analogues
FZ_pmb and FZ_tol were synthesized by direct condensation of FZ
with corresponding carboxylic acids in presence of N,N-dicyclohexyl
carbodiimide (DCC) under cold condition. Purity of the compounds has
been checked by assigning 1H and 13C NMR spectra (Supplementaries 1
and 2) and TLC analysis. Yields, M.P., IR and 1H and 13C NMR spectral
data are given in Table 1. The details of the synthesis method are
discussed elsewhere [12].
2.3. Standardization of the culture
Standardization of the culture was done with McFarland's
turbidity standard using spectrophotometric method [13]. The test
organisms were incubated at 35 °C for 24 h on Sabouraud dextrose
agar Petri plates. The inoculum's suspension was prepared by picking
ﬁve colonies of at least 1 mmdiameter and suspending thematerial in
5 ml sterile 0.85% NaCl solution. The turbidity of the cell suspension
wasmeasured at 530 nm andwas adjusted with sterile saline solution
to match that of a 0.5 McFarland's turbidity standard. This procedureprovided a cell suspension containing 1.5×108 cells/ml which was
then diluted (1:100) with sterile 0.85% NaCl to provide a starting
inoculum of 1.5×106 cells/ml.
2.4. Procedure for antifungal testing
2.4.1. Determination of minimum inhibitory concentration by
conventional methods
Minimum inhibitory concentration (MIC) is the lowest concen-
tration of drug inhibiting visible growth of fungi after 48 h of
incubation. Two conventional methods, tube dilution (8, 9) and
broth microdilution [7] methods were used for MIC determination.
After the incubation of the culture, end point was assessed visually
and expressed as μg/ml.
2.4.2. Tube dilution method
In Tube dilution method a set of tubes with different concentra-
tions of drug were prepared (Fig. 2). The tubes were then inoculated
with the C. albicans ATCC 10231 incubated at 35 °C for 48 h, and
examined for growth of cells. Growth is seen to diminish as the
concentration of drug increases, and eventually a drug concentration
is observed at which growth fails to occur.
KZ, FZ and FZ analogues were dissolved in dimethyl sulfoxide
(DMSO) to get stock solution of 2500 μg/ml. These drug solutions
were then serially diluted with Sabouraud dextrose broth to get
concentrations from 10 to 1000 μg/ml for KZ and 1 to 1000 μg/ml for
FZ and its analogues. A 50 μl of standardized suspension of C. albicans
ATCC 10231 containing 1.5×106 cells per ml was inoculated into each
test tube and incubated at 35 °C for 48 h. Positive and negative
controls were included in each run. Growth of cells was monitored
after 48 h and the results of these observations are indicated in
Table 2.
2.4.3. Broth microdilution method
KZ, FZ and analogues were dissolved in DMSO to get a stock
solution of 200 μg/ml. Drug solutions were then serially diluted with
RPMI-1640, supplemented with 2%-glucose (wt/vol) and buffered at
pH 7 with 0.165 M 3-(N-morpholino) propanesulfonic acid to get
concentrations of drug from 1 to 100 μg/ml. Isolates were recovered
Table 1
Yield, physical and spectroscopic data of ketoconazole, ﬂuconazole and ﬂuconazole analogues.
Drug M.P (°C) Yield (%) Mol. formula IR (cm−1) 1H NMRa 13C NMR
KZ 146 – C26H28Cl2N4O4 2883.58,
1647.21
1583.56
1051.20
815.89
2.11 CH3 (1), 3.028 CH2 (4,8),
3.351 CH (16), 3.583 CH2 (28),
3.732 CH2 (5,7), 3.856 CH (16),
4.311 CH (17), 4.40 CH (21)
4.46 CH (21),6.768 CH (10,14)
6.851 CH (11,13), 6.927 CH (27),
7.223 CH (31), 7.438 CH (30),
7.471 CH (26), 7.539 CH (24),
7.556 CH (33)
C2(169), C12(153.2), C9 (45.9),
C30 (138.8), C23 (135.9), C22 (134.6),
C25 (132.9), C24 (131.7), C27 (129.7),
C32 (128.6), C26 (127.5), C33 (121.3),
C10, 14 (119.1), C11, 13 (115.1), C19 (108.2),
C17 (77), C16 (74.7), C21 (67.6),
C5, 28 (51), C7 (46.3), C4 (41.3) ,
C8 (29.7), C1 (21.5)
FZ 138 – C13H12F2N6O 3153.61,
2956.87,
1618.28
4.57 CH (8A), 4.73 CH (8B),
6.5 OH (9), 6.85 CH (6),
7.12 CH (5), 7.17 CH (3),
7.78 CH (3′), 8.30 CH (5′)
C2 (163.5), C4 (160.5), C3′ (151.2),
C5′ (145.6), C6 (130.1), C1 (123.7),
C5 (111.2), C3 (104.1), C7 (74.2),
C8 (55.5)
FZ_bz 92–95 75 C20H16F2N6O2 2933.73,
1653,
1712.79
1253.73
7.49 CH (12,14), 7.61 CH (13),
7.93 CH (11,15)
C9 (167.8), C2 (162.8), C4 (160.7), C3′ (149),
C5′(145.2), C6 (135.7), C13 (130.9),
C11,15 (129.7), C12,14 (129.1), C1 (123.6),
C5 (111.6), C3 (104.5), C7 (73.9), C8 (55.72)
FZ_pnb 67–70 87 C20H15F2N7O4 2954.95,
1608.63,
1701.22,
1278.81
7.99 CH (11,15), 8.65 CH (12,14) C9 (166.4), C2 (163.6), C4 (158.6),
C13 (150.5), C3′ (149.9), C5′ (145.2),
C10 (136.8), C11,15 (131.2), C6 (130.1),
C12,14 (124.2), C1 (123.6), C5 (111.6),
C3 (104.5), C7 (74), C8 (55.53)
FZ_pmb 125–127 62 C14H18F2N6O3 2933.73,
1606.7,
1710.86,
1274.95,
1340.53
3.827 CH3 (17), 6.901 CH(12,14),
7.438 CH (11,15)
C9 (171), C13 (168.4), C2 (165.9),
C4 (163.6), C3′ (161.4), C5′ (154.9),
C10 (131.5), C6 (130.3), C11,15 (129.5),
C1(122.7), C5 (114.4),C12,14 (113.7) ,
C3 (113) ,C7 (60.8) , C8 (55.8),
C17 (54.4)
FZ_tol 113–115 60 C14H18F2N6O2 2929.87,
1650,
1697.36
1234.44,
1336.97
2.347 CH3 (16), 7.282 CH (12,14)
7.772 CH (11,15)
C9 (163.5), C2 (161.1), C4 (154.9),
C3′ (151.4), C5′ (145.8), C13 (135),
C11,15 (129.9), C6,10 (128.8), C12,14 (127.7),
C1 (124), C5 (111.6), C3 (104.6),
C7 (74.2), C8 (55.4), C16 (21.8)
a The numbering scheme is shown in Fig. 1. In case of ﬂucanozole analogues, 1H and 13C assignments are given only for group –R.
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The isolates were then adjusted to a concentration of 0.5×103 to
2.5×103 cells/ml in supplemented RPMI medium. A 100 μl of aliquots
was dispensed into tubes containing drugs. Growth and sterility
controls were included in each run. Growth of cells was monitored
after 24 h and the results of these observations are indicated in
Table 3. MICs were determined at 24 h visually by comparing the
turbidity of samples with positive as well as negative control.Fig. 2. Representative diagram showing standard procedure for Tube dilution method.2.4.4. Determination of Metabolic End Point (MEP) by NMR method
Metabolic End Point (MEP) is lowest concentration of the drug that
corresponds to≥50% reduction in fungalmetabolite production. It has
been determined by using 1H NMR technique.
2.5. NMR technique
Due to sensitivity reasons, in NMR experiments instead of using
0.5 McFarland's we have used 2.0 McFarland's standard culture which
resulted in higher production of fungal metabolites and can be easily
detected in 1H NMR spectra. Serial dilutions of drugs in Sabouraud
dextrose broth were dispensed in 1 ml of aliquots into eppendorff
tubes. These tubes were then incubated at 35 °C for 18, 24 and 32 h.
After incubation for speciﬁc time period, tubes were centrifuged for
30 min at 4000 rpm. Supernatant was discarded and cells were
washed twice with phosphate buffered saline (PBS) solution. Finally,
cells were suspended in 0.6 ml PBS and were transferred to 5-mm
NMR tubes. A 10 μl of D2O was added to each NMR tube to provide a
ﬁeld frequency lock.
1H NMR spectra were recorded at 500 MHz BRUKER NMR
spectrometer. Sixty-four transients were collected with a repetition
time of 2 min for each sample at a temperature of 298 K. Water
suppression was performed by a selective-excitation ﬁeld-gradient
method. Chemical shift referencing was done using water resonance
at 4.64 ppm with respect to 2,2,3,3-tetradeutero-3-trimethylsilyl
propionic acid (TSP) [14].
COSY spectrum was recorded using standard pulse technique
[15–17]. 1D 1H NMR spectra were recorded for cells incubated
at different drug concentrations and for different time intervals
taking care of various NMR parameters such as relaxation delay,
acquisition time, number of transients, receiver gain etc. ﬁxed for
Table 2
Results of fungal testing in presence of varying concentration of ketoconazole, ﬂuconazole and ﬂuconazole analogues as determined by Tube dilution method. (Details of the method
are given in the text.)
Drugs/
analogs
Concentration in μg/ml
1 1.5 2 2.5 3 3.5 4 4.5 5 5.5 6 6.5 7 7.5 8 8.5 9 9.5 10 25 50 100 200 500 1000
KZ + + + + + + + + + + + + + + + + + + + + − − − − −
FZ + + − − − − − − − − − − − − − − − − − − − − − − −
FZ_bz + + − − − − − − − − − − − − − − − − − − − − − − −
FZ_pmb + − − − − − − − − − − − − − − − − − − − − − − − −
FZ_tol + + + + + + + + + + − − − − − − − − − − − − − − −
FZ_pnb + + + + + + + + + + + + + + + + + + + − − − − − −
Presence and absence of growth is indicated by ‘+’ and ‘−’, respectively.
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was compared for the various time points, at different drug
concentrations by integrating the signals from ethanol, lactate and
acetate using inbuilt NMR software.
Stack plots of NMR spectra were constructed to show the effect of
different concentrations of drug pressure on production of fungal
metabolites. To obtain a quantiﬁable endpoint, integralswere calculated
for resonance of ethanol (1H δ 1.18–1.2), lactate (1H δ 1.3–1.35), and
acetate (1H δ 1.8–1.94) [18,19]. Peak integrals were determined for
these metabolites and were normalized and calculated relative to the
corresponding integrals in the positive control sample. MEP could be
determined from the plots of signal intensity vs. drug concentration, as
the lowest concentration of drug atwhich fungalmetabolite production
was inhibited by ≥50%.
3. Results
Conventional methods used to calculate MIC require long time to
yield results andmay be inﬂuenced by the conditions under which the
tests are performed. Moreover, the sensitivity and speciﬁcity of
conventional methods are generally low. However, determination of
MIC by conventional methods forms the important basic laboratory
methods [20]. Metabolic proﬁling using NMR yields objective end-
points (MEPs). These are internally consistent for multiple metabo-
lites. The method is substantially faster than, yet yields results that
correlate with, conventional methods.
3.1. Tube dilution experiments
Growth of the cells was monitored in presence of KZ, FZ and FZ
analogues using tube dilutionmethod as shown in Fig. 2. The turbidity
of the samples was compared with positive as well as negative
controls after incubation for 48 h at 35 °C. The results of fungal testing
i.e. presence and absence of cell growth is indicated in Tables 2 and 3.
MIC was determined in each case and indicated in Table 4. It is
observed that KZ has very largeMIC value 50 μg/ml as compared to FZ
with 2 μg/ml (Table 4). These results are consistent with the literature
reports [21]. Whereas, the comparison of MIC values of analogues
indicates that FZ_pmb has MIC 1.5 μg/ml which is the lowest asTable 3
Results of fungal testing in presence of varying concentration of ketoconazole,
ﬂuconazole and ﬂuconazole analogues as determined using CLSI-mod method.
Drugs/
analogs
Concentration in μg/ml
1 5 10 25 50 100
KZ + + + − − −
FZ − − − − − −
FZ_bz − − − − − −
FZ_pmb − − − − − −
FZ_tol + − − − − −
FZ_pnb + − − − − −
Presence and absence of growth is indicated by ‘+’ and ‘−’, respectively.compared to FZ and other analogues. The FZ and FZ_bz have MIC
values 2 μg/ml with equal inhibition activity. FZ_tol with MIC 6 μg/ml
and FZ_pnb with MIC 25 show comparatively less inhibitory effect.
Thus among the synthesized FZ analogues, FZ_pmb is found to be
most active as compared to FZ_pnb which shows least inhibitory
effect. Fz_bz and FZ_tol have intermediate inhibitory effect.
3.2. Broth microdilution experiments
The Broth micro dilution method is a modiﬁcation of the US
Clinical and Laboratory Standards Institute (CLSI) [10]. This method
helps in rapid determination of antifungal susceptibility by providing
satisfactory 24 h visual endpoints as compared to the 48 h studies in
Tube dilution method (Table 3). This is reported to be due to the
higher concentrations of glucose used in this method, which enhances
fungal growth without signiﬁcantly changing MICs of drugs [22]. It is
observed from these experiments that the MIC values follow similar
trend (Table 4) as observed using tube dilution method. KZ shows
very high value 25 μg/ml as compared to FZ with 1 μg/ml. Other
analogues FZ_bz and Fz_pmb have identical values 1 μg/ml each and
FZ_pnb and FZ_tol with 5 μg/ml each. Among all the synthesized FZ
analogues, FZ_pmb and FZ_bz show inhibitory action compared to FZ.
Whereas FZ_pnb and FZ_tol have comparatively lower inhibitory
effect. Test could not be performed at less than 1 μg/ml drug
concentration due to the limitations related to this method.
3.3. NMR experiments
1D proton NMR spectra of C. albicans ATCC 10231 incubated with
various concentrations of KZ, FZ and analogues have been recorded at
18, 24 and 32 h. Metabolites have been identiﬁed by using 2D
correlation spectrum (COSY) [16–18] (Fig. 3), spiking method and
using chemical shifts from literature [19,20]. A representative 1D 1H
NMR spectrum of C. albicans ATCC 10231 with assignments of
metabolites is shown in Fig. 4. The resonances from PBS-saline and
from metabolites including ethanol, lactate, acetate, succinate and
pyruvate have been assigned and indicated. Various metabolitesTable 4
Comparison of MEPs obtained by NMR method with MICs obtained by conventional
methods.
Name
of the
drug
MIC by conventional
methods (μg/ml)
MEP by NMR method (μg/ml)
Ethanol Lactate Acetate
Tube dilution
(48 h)
CSLI-mod
(24 h)
18 24 32 18 24 32 18 24 32
KZ 50 25 35 35 10 35 15 15 40 25 20
FZ 2 b1 1 1 1 7 1 1 4 1 1
FZ_bz 2 b1 1 2 1 0.5 7 1 1 10 1
FZ_pnb 25 5 4 19 18 3 6 15 4 9 8
FZ_pmb 1.5 b1 1 1 1 0.5 1 3 1 3 2
FZ_tol 6 5 3 6 5 2.5 13 1 2.5 10 9
Fig. 3. Portion of 500 MHz 2D-COSY spectrum of C. albicans ATCC 10231 indicating
assignments of ethanol-CH3 and lactate-CH3 proton signals.
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at different time intervals. This method provides advantage over
conventional method mentioned above as we could monitor the
metabolites at a lower time period of incubation such as 18 h in
addition to 24 and 32 h. Therefore, it is possible to observe early
inhibitory effect of the drugs. The most prominent changes in
metabolite concentrations after incubation of C. albicans ATCC 10231
with drugs are observed in 0.5–3.0 ppm region of the 1H NMR spectra.
When 1H NMR spectra at 18, 24 and 32 h are compared with growth
controls, clear cut and consistent reduction in metabolic concentra-
tions by at least 50% are observed for all the drugs and analogues.
Stack plots of 1H NMR spectra have been constructed to show the
effect of drug on production of fungal metabolites (Figs. 5 and 6). In
case of ketoconazole and ﬂuconazole the onset of inhibition is clearly
indicated at 25 and 1 μg/ml drug concentrations, respectively. Similar
metabolic inhibitions are observed for C. albicans ATCC 10231 for
ﬂuconazole analogues also (ﬁgures not shown). Indicative metabolic
end points (MEPs) could be determined from spectral peaks'Fig. 4. A 500-MHz 1H NMR spectrum of 24 h culture of C. albicanintensities as the lowest concentration of drug at which fungal
metabolite production is inhibited by at least 50%. To support the
hypothesis that drug induced metabolic changes detected by NMR
technique are evident before visible growth inhibition of fungi, the
MEPs obtained at 18 h may be compared with MICs determined by
conventional Tube dilution and Broth microdilution methods
(Table 4). Results obtained by NMR technique are found to be
consistent with MICs obtained by conventional methods.
Ethanol, lactate and acetate intensities have been monitored in the
NMR spectra as a function of drug concentration. The intensity of
ethanol, lactate and acetate peaks decreases with increasing concen-
tration of drug (Figs. 7 and 8). In general, it is observed that the initial
decrease in the metabolite peak intensity is very rapid and stabilizes
with increasing concentrations of drug. For, FZ, FZ_bz and FZ_pmb
(Fig. 8, curves I, II, and IV) relatively sharp changes occur over a
narrow range of drug concentrations, and eventually plateaus. This is
probably because the effective drug concentration is limited by the
rate of drug diffusion to its molecular targets. In case of ketoconazole,
FZ_pnb and FZ_tol, more gradual changes were noted. Further it is
noted that FZ_pnb (Fig. 8, curves III) shows a relatively sharp decrease
in ethanol, lactate and acetate concentration (a fall of about 75–80%)
at low drug concentration (~5 μg/ml) in cells incubated for 18 h.
However, the effect is slow, gradual and sensitive to the drug
concentration at higher incubation times i.e. 24 and 32 h. On the
other hand, effect of FZ_pmb (Fig. 8, curve IV) shows a very consistent
and sharp decrease (a fall of about 95% at N5 μg/ml drug concentra-
tion) in all metabolites and at all incubation times.
The MEP was determined from these plots for 18, 24 and 32 h. It is
observed that in all the cases metabolic inhibition starts at 18 h itself.
In case of KZ the MEP value decreases with increasing incubation time
from 18 to 32 h. The change in MEP values for ethanol, lactate and
acetate varies between 20 and 40 μg/ml. This is consistent with the
values determined using conventional Tube dilution and CSLI
methods which is 50 and 25 μg/ml, respectively (Table 4).
However, in case of ﬂuconazole, the drug required for 50%
inhibition is order of magnitude less as compared to ketoconazole.
The MEP value at 18 h is 1 μg/ml and it continues to be in the same
range at all times of incubation. This very well agrees with the MIC
values determined by the conventional methods (Table 4). The MEP
values calculated for ﬂuconazole derivatives vary differently depend-
ing upon the type of substitution. In case of FZ_bz and FZ_pmb the
MEP values are comparable to those of ﬂuconazole and decrease or
remain unchanged with increasing incubation time. However, in cases ATCC 10231 indicating assignments of various metabolites.
Fig. 5. Representative 1H NMR spectra of C. albicans ATCC 10231 in presence of different concentrations of ketoconazole incubated for a) 18 h, b) 24 h and c) 32 h. Numbers on the
right indicate concentrations of drug (μg/ml) used. Concentration dependent changes in fungal metabolite production are seen.
Fig. 6. Representative 1H NMR spectra of C. albicans ATCC 10231 in presence of different concentrations of ﬂuconazole incubated for a) 18 h, b) 24 h and c) 32 h. Numbers on the right
indicate concentrations of drug (μg/ml) used. Concentration dependent changes in fungal metabolite production are seen.
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Fig. 7. Time course of the effect of ketoconazole (upper panel) and ﬂuconazole (lower panel) on proﬁles of selected metabolites. The ﬁgure shows changes in ethanol, lactate and
acetate production by C. albicans ATCC 10231 incubate for I) 18 h, II) 24 h and III) for 32 h. The x-axis shows the drug concentration (μg/ml); the y-axis shows the relative integral.
Each graph displays results from one of duplicate experiments.
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the range of MIC values observed using conventional methods.
Moreover, in case of FZ_pnb and FZ_tol, for all the metabolites
(ethanol, lactate and acetate), MEP value is lower at 18 h and does not
decrease with increasing incubation time as expected and as observed
in the case of KZ, FZ, FZ_bz and FZ_pmb.
4. Discussion
In general these results indicate an internally consistent MEP
values for various metabolites, the small variations observed could be
due to mixed fermentation products expected during growth under
anaerobic conditions in the presence of excess carbon substrate (in
this case 2% glucose). Moreover these results indicate that the
mechanism of cell killing by these agents is both time dependent as
well as concentration dependent [23].
In case of ﬂuconazole analogues FZ_pnb and FZ_tol there is
paradoxical increase in MEP values with increasing incubation time
[24]. It is observed that for ethanol, lactate and acetate, MEP values are
higher at 24 and 32 h incubation as compared to those of 18 h
incubation. The effect is speciﬁc to theses two analogues, since it is not
observed with other analogues. These speciﬁc effects could be due to
the spontaneous chromosomal mutation to the cells leading to drug
resistance [25].
Our study indicates that the in vitro antifungal activity for FZ
analogues clearly dependent upon the nature of substituent(s)
attached to FZ. All analogues of FZ show signiﬁcant antifungal activity
against C. albicans ATCC 10231 when tested using conventional as
well as NMR techniques. Both methods exhibit comparable results for
all the test compounds. FZ_pmb shows higher activity than FZ, FZ_bz
shows comparable activity with FZ, FZ_pnb and FZ_tol show lesser
activity than FZ.5. Conclusions
Metabolic proﬁling of microbial species can provide information
on the effect of drug on microbial metabolic pathways which is
directly related to the viability of the cell. Firstly, the present study
highlights the application of NMR spectroscopy to determine the
metabolic composition of microbial suspension incubated with range
of drugs/drug like agents. It is a valuable method for the rapid
antimicrobial screening useful in the process of high throughput
testing of newly synthesized agents as well as suitable for use in large
diagnostic reference laboratories. Apart from the rapidity, direct NMR
based evaluation of metabolic variations can also provide any
signiﬁcant changes in the normal metabolic pathways of cell cultures
that can be crucial information regarding susceptibility of antifungal
drugs.
Secondly, our study using NMRmethod yields prominent results at
18 h which is considerably less than 48 h by conventional microbial
tests. At the same time the results are consistent with those of
conventional methods.
Out of the four synthesized analogues of FZ, FZ_pmb is potentially
more active than FZ. FZ_bz shows equivalent activity to FZ indicating
that esters synthesized by attaching various substituents at OH
position of FZ may be promising candidates for antifungal activity and
further studies in this direction may be helpful in the development of
new antifungal agents to overcome the problems of resistance and
reduced susceptibility.
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